SXTC revenueFY2026$1.14M
- FY YoY
- -34.6%
- 5Y CAGR
- -24.9%
SXTC revenue was $1.14M for fiscal 2026 (ended Mar 31, 2026), down 34.6% from fiscal 2025. Compound annual growth was -24.9% over 5 years. It rose in 1 of the last 9 fiscal years.
China SXT Pharmaceuticals Inc. (SXTC) financials
For fiscal 2026 (ended Mar 31, 2026), China SXT Pharmaceuticals Inc. reported $1.14M of revenue and -$6.21M of net income.
- Revenue, FY2026
- $1.14M
- Revenue growth, YoY
- -34.6%
- Net income, FY2026
- -$6.21M
- Net margin
- -545.2%
- EPS, diluted, FY2026
- -$9.13
- Cash
- $28.18M
- Total debt
- $999.6K
- P/S
- 0.28
- Market cap
- $321,082
FY2017FY2026
FY2017FY2026
FY2017FY2025
SXTC revenue and earnings growth
SXTC net incomeFY2026-$6.21M
SXTC net income was -$6.21M for fiscal 2026 (ended Mar 31, 2026), compared with -$3.30M in fiscal 2025.
SXTC EPSFY2026-$9.13
SXTC diluted EPS was -$9.13 for fiscal 2026 (ended Mar 31, 2026).
SXTC free cash flowFY2025-$2.35M
SXTC free cash flow was -$2.35M for fiscal 2025 (ended Mar 31, 2025), compared with -$1.94M in fiscal 2024.
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.14M | $1.74M | $1.93M | $1.97M | $2.60M | $4.78M | $5.16M | $7.01M | $7.02M | $4.88M |
| Cost of revenue | $889.4K | $1.37M | $1.37M | $1.55M | $1.35M | $1.94M | $2.46M | $2.40M | $3.62M | $2.57M |
| Gross profit | $248.7K | $367.4K | $554.0K | $426.3K | $1.25M | $2.84M | $2.70M | $4.61M | $3.40M | $2.31M |
| Research and development | - | - | $184.2K | $200.7K | $367.0K | - | - | - | - | - |
| Selling, general and admin | $7.13M | $2.76M | $2.64M | $5.65M | $5.52M | $3.45M | $2.46M | $1.24M | $1.26M | $565.5K |
| Operating income | -$7.12M | -$2.68M | -$2.52M | -$5.61M | -$5.19M | -$2.20M | -$1.34M | $1.77M | $1.63M | $1.60M |
| Interest expense | $63.0K | $648.2K | $544.3K | $476.8K | $36.7K | $1.62M | $3.35M | $5.2K | $779 | $40.4K |
| Pre-tax income | -$6.21M | -$3.30M | -$3.10M | -$5.93M | -$5.41M | -$2.94M | -$10.39M | $1.79M | $1.63M | $1.58M |
| Income tax | - | - | - | - | $328.1K | -$192.7K | -$101.7K | $252.2K | $440.1K | $395.0K |
| Net income | -$6.21M | -$3.30M | -$3.10M | -$5.93M | -$5.74M | -$2.75M | -$10.29M | $1.54M | $1.19M | $1.19M |
| EPS, basic | -$9.13 | -$348.17 | -$4285.66 | -$26675.55 | -$165501.60 | -$114570.00 | $998460.00 | -$8970.00 | $1770.00 | $1770.00 |
| EPS, diluted | -$9.13 | -$348.17 | -$4285.66 | -$26675.55 | -$165501.60 | -$114570.00 | $49920.00 | -$8970.00 | $1770.00 | $1770.00 |
| Diluted shares | 679,648 | 9,489 | 723 | 222.48 | 34.659 | 23.985 | 206.072 | 171.405 | 666.667 | 666.667 |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $28.18M | $18.10M | $12.08M | $17.37M | $15.57M | $13.36M | $7.29M | $9.29M | $657.8K | $65.6K |
| Receivables | $931.6K | $1.30M | $1.31M | $1.34M | $3.33M | $4.51M | $3.82M | $4.18M | $2.60M | - |
| Inventory | $777.1K | $828.1K | $794.9K | $531.3K | $1.02M | $859.7K | $892.8K | $1.01M | $1.27M | - |
| Current assets | $34.51M | $21.30M | $14.23M | $19.52M | $22.45M | $23.23M | $19.64M | $15.59M | $6.10M | - |
| Total assets | $34.75M | $21.66M | $23.13M | $29.55M | $33.55M | $34.55M | $21.70M | $17.47M | $7.66M | - |
| Current liabilities | $4.35M | $6.01M | $8.90M | $14.50M | $17.12M | $18.58M | $12.26M | $6.32M | $4.37M | - |
| Short-term debt | $355.2K | $8.8K | $21.3K | $7.9K | $11.4K | $37.1K | $43.9K | $27.8K | - | - |
| Long-term debt | $644.4K | $96.3K | $117.1K | $117.9K | - | - | - | - | - | - |
| Total debt | $999.6K | $105.0K | $138.5K | $125.7K | - | $6.3K | $36.5K | $41.7K | - | - |
| Total liabilities | $5.05M | $6.22M | $9.20M | $14.86M | $17.12M | $18.59M | $12.30M | $6.36M | $4.37M | - |
| Shareholders' equity | $29.71M | $15.44M | $13.93M | $14.69M | $16.08M | $15.96M | $9.40M | $11.11M | $3.29M | $1.85M |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.02M | -$2.35M | -$1.93M | -$80.8K | $268.3K | -$1.32M | $934.2K | $239.2K | $1.92M | $293.0K |
| Capital expenditures | - | $2.0K | $7.1K | - | - | - | $130.8K | $535.8K | $436.0K | $179.2K |
| Free cash flow | - | -$2.35M | -$1.94M | - | - | - | $803.4K | -$296.6K | $1.48M | $113.9K |
| Investing cash flow | -$1.25M | $63.5K | $26.4K | -$12.3K | -$46.9K | -$5.81M | -$5.50M | -$610.1K | -$1.05M | -$186.3K |
| Financing cash flow | $14.43M | $8.40M | -$2.62M | $2.94M | $1.60M | $12.41M | $3.02M | $9.04M | -$314.2K | -$50.6K |
| Stock-based compensation | $5.31M | - | $352.1K | $554.6K | $2.33M | - | - | - | - | - |
| Depreciation and amortization | $73.7K | $82.3K | $203.2K | $250.2K | $320.0K | $345.4K | $331.8K | $180.9K | $129.4K | - |
Key ratios
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -34.6% | -9.7% | -2.2% | -24.2% | -45.5% | -7.5% | -26.4% | -0.1% | 43.8% | - |
| Net income growth, YoY | - | - | - | - | - | - | - | 29.6% | 0.2% | - |
| EPS growth, YoY | - | - | - | - | - | - | - | - | 0.0% | - |
| Gross margin | 21.9% | 21.1% | 28.7% | 21.6% | 48.1% | 59.4% | 52.4% | 65.8% | 48.5% | 47.4% |
| Operating margin | -625.9% | -154.0% | -130.4% | -284.4% | -199.4% | -46.0% | -26.0% | 25.2% | 23.3% | 32.8% |
| Net margin | -545.2% | -189.8% | -160.7% | -301.0% | -220.4% | -57.5% | -199.3% | 22.0% | 16.9% | 24.3% |
| Free cash flow margin | - | -134.8% | -100.3% | - | - | - | 15.6% | -4.2% | 21.1% | 2.3% |
| Return on equity | -20.9% | -21.4% | -22.2% | -40.4% | -35.7% | -17.2% | -109.4% | 13.9% | 36.1% | 64.0% |
| Return on assets | -17.9% | -15.2% | -13.4% | -20.1% | -17.1% | -8.0% | -47.4% | 8.8% | 15.5% | - |
| Current ratio | 7.93 | 3.54 | 1.60 | 1.35 | 1.31 | 1.25 | 1.60 | 2.47 | 1.40 | - |
| Debt to equity | 0.03 | 0.01 | 0.01 | 0.01 | - | 0.00 | 0.00 | 0.00 | - | - |
Source: XBRL data China SXT Pharmaceuticals Inc. files with the SEC, latest filing dated Jul 1, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Aug 13, 2024; 1-for-8, first reported Jul 31, 2025; 1-for-150, first reported Jul 1, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
SXTC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SXTC | $1.14M | -34.6% | -$6.21M | -545.2% | $321,082 |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
SXTC FAQ
8 questionsWhat is SXTC revenue?
China SXT Pharmaceuticals Inc. (SXTC) reported $1.14M of revenue for fiscal 2026 (ended Mar 31, 2026). That is down 34.6% from the year before.Is SXTC profitable?
No. China SXT Pharmaceuticals Inc. reported a net loss of $6.21M for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does SXTC have?
China SXT Pharmaceuticals Inc. reported $28.18M in cash and cash equivalents and $999.6K of debt on its most recent balance sheet in SEC filings.How fast is SXTC revenue growing?
China SXT Pharmaceuticals Inc.'s revenue changed -34.6% in fiscal 2026, to $1.14M. Its compound annual growth rate was -24.9% over 5 years.What is SXTC gross margin?
China SXT Pharmaceuticals Inc.'s gross profit was $248.7K on $1.14M of revenue for fiscal 2026 (ended Mar 31, 2026), a gross margin of 21.9%.What is SXTC earnings per share?
Diluted earnings per share were -$9.13 for fiscal 2026 (ended Mar 31, 2026), from SEC filings, restated for any stock split those filings show.When did SXTC last report financial results?
The latest statements here come from China SXT Pharmaceuticals Inc.'s 20-F filed on Jul 1, 2026, covering the period ended Mar 31, 2026.Where does this SXTC financial data come from?
Quantisnow builds these statements from the structured XBRL data China SXT Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.